Well, if our median survival is less than a year, I think you can compare it to that of the other two drugs, which are stated in your mail. I do think a bunch of conditions were ruled out for Trodelvy which were allowed in our trial, like brain mets, so that is a mitigating factor in our favor. So it's not quite apples versus apples.